FDA Confirms 13 Cases of Progressive Multifocal Leukoencephalopathy in Patients Receiving Natalizumab (Tysabri) for Multiple Sclerosis

FDA reports 13 confirmed cases of progressive multifocal leukoencephalopathy from patients taking Tysabri